SCHEMBL12929524

SCHEMBL12929524

CCOC(=O)c1cnc(N2CCCCC2CO)nc1N(C)C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.53
▸ NPSR1 Q6W5P4 3/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ ALOX15 P16050 2/20 0.53
▸ NPC1 O15118 2/20 0.53
▸ RAB9A P51151 2/20 0.53
▸ TP53 P04637 1/20 0.53
▸ LMNA P02545 2/20 0.43
▸ NR2F2 P24468 2/20 0.41
▸ MAPT P10636 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ S1PR2 O95136 1/20 0.41
▸ XBP1 P17861 1/20 0.41
▸ PPP1CA P62136 1/20 0.41
▸ CSNK1D P48730 1/20 0.40
▸ PDE5A O76074 2/20 0.40
▸ FOS P01100 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12929652 0.81 ALDH1A1 (0.63) ALDH1A1NPSR1SMN1; SMN2ALOX15NPC1
SCHEMBL12929736 0.80 ALDH1A1 (0.61) ALDH1A1NPSR1SMN1; SMN2ALOX15NPC1
SCHEMBL12929636 0.79 ALDH1A1 (0.53) ALDH1A1NPSR1SMN1; SMN2ALOX15NPC1
SCHEMBL31143603 0.77 HDAC6 (0.51) MAPTMKNK1MKNK2AOC3POLB
SCHEMBL12929334 0.76 ALDH1A1 (0.59) ALDH1A1NPSR1SMN1; SMN2ALOX15NPC1
SCHEMBL12929669 0.76 ALDH1A1 (0.56) ALDH1A1NPSR1SMN1; SMN2ALOX15NPC1
SCHEMBL5250807 0.76 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2LMNAMAPTMAPK1
SCHEMBL5250804 0.76 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2LMNAMAPTMAPK1
SCHEMBL13121894 0.75 ALDH1A1 (0.58) ALDH1A1NPSR1SMN1; SMN2ALOX15NPC1
SCHEMBL12929546 0.75 ALDH1A1 (0.60) ALDH1A1NPSR1SMN1; SMN2ALOX15NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324220-B2 Pyrimidines useful as modulators of voltage-gated ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-12-04 — — US disclosed
US-8324220-B2 Pyrimidines useful as modulators of voltage-gated ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-12-04 — — US disclosed
US-20110003814-A1 PYRIMIDINES USEFUL AS MODULATORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-01-06 — — US disclosed
US-20110003814-A1 PYRIMIDINES USEFUL AS MODULATORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-01-06 — — US disclosed
US-7816529-B2 Pyrimidines useful as modulators of voltage-gated ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-19 — — US disclosed
US-7816529-B2 Pyrimidines useful as modulators of voltage-gated ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003814-A1 PYRIMIDINES USEFUL AS MODULATORS OF VOLTAGE-GATED ION CHANNELS KCNJ1, KCNJ11, TRPV1 ALDH1A1 2361/4885NPSR1 2654/4885SMN1; SMN2 1190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback